ABCL AbCellera Biologics Inc

$ABCL Called the reversal from $3–$4 when the short-covering was just brewing—check my posts since last November predicting the entire run to $12+. 🎯 ​The setup is shifting from a short-covering bounce to a full institutional re-rating: ​• P1 : 18M+ shorts covered, balance sheet locked down with $200M in cash. • P2: Pullback from $15 into the 12, cooled RSI right into major catalysts. ​Why the next leg is setting up: ​TMS Conference (Oct 22): Granular Phase 1/2 ABCL635 data drops in days. Top-line efficacy is already proven; clean safety and differentiation will drive the next wave. ​Wall St. Taking Notice: Analyst upgrades are already rolling in. Institutional accumulation is underway, and value investors need to move before the window closes. ​Q3 Earnings (Nov 9): Partner milestone updates (Vertex, Jazz) and pipeline clarity on ABCL688. ​This isn't just about trapped shorts anymore—it’s about $ABCL getting repriced as a validated clinical biotech. Eyes on the tape this week.

$ABCL Maybe we get some positive news after hours today? Trap the bears on a solid run to 16 from Monday to Friday. Let’s gooooo!!

$ABCL Carl knows what he is doing! This Thursday is going to CATCH EVERYBODY OFF GUARD!!! We are going to get SOME BIG NEWS 🗞️!! 🔥 Mark this POST‼️🚨👀

$ABCL News 📰 Ahead of Thursday 👏 , 2026 TMS Conference in 3 days 🔥Lets GO!!! I think Carl wants to catch Shorts and traders off GUARD and really give us some EXPLOSIVE 🧨 DATA 📊 before then and 💯 on Thursday!!! Read the PR TWICE!! Read the last sentence a few times!! 🔥

$ABCL Love that UBS analysis at $18. Lowest updated one I’ve seen is $13, and most are in the $15-$30 - going to be a big year!!

$ABCL gave you the bottom almost to penny and the top both days almost on this run from 1.89 to 15

Called the $ABCL reversal from $3–$4 when the short-covering was just brewing—check my posts since last November predicting the entire run to $12+. 🎯 ​The setup is shifting from a short-covering bounce to a full institutional re-rating: ​• P1 Done: 18M+ shorts covered, balance sheet locked down with $200M in cash. • P2 Loading: Pullback from $15 into the 12, cooled RSI right into major catalysts. ​Why the next leg is setting up: ​TMS Conference (Oct 22): Granular Phase 1/2 ABCL635 data drops in days. Top-line efficacy is already proven; clean safety and differentiation will drive the next wave. ​Wall St. Taking Notice: Analyst upgrades are already rolling in. Institutional accumulation is underway, and value investors need to move before the window closes. ​Q3 Earnings (Nov 9): Partner milestone updates (Vertex, Jazz) and pipeline clarity on ABCL688. ​This isn't just about trapped shorts anymore—it’s about $ABCL getting repriced as a validated clinical biotech. Eyes on the tape this week.

$ABCL Wow, 320k bought at 10:07, another 133k at 11:54 - huge volume and price soaring with no news. Something know something I don't??

$ABCL 100%. I usually don't post more than a sentence or two, but these rich asshats and their puppets have been jerking this thing back and forth for a while now. 😂😭 Let them play their games. I’ve learned, that they can’t manipulate—PATIENCE. I’ve been in ABCL since it was down around $3. I’ve banked some nice profits along the way, added and traded around my position, and I’m still sitting on plenty of shares for what I believe could be the REAL payday. 💰 I do my own DD and usually keep it to myself! Nothing in biotech is guaranteed. But here’s what has me excited: ABCL does NOT need every program to become a blockbuster. Start getting successful drug candidates into the clinic, advancing through trials, and eventually reaching commercialization—and suddenly you’re talking milestones, royalties, and potentially multiple shots on goal. That’s when this story could get VERY interesting. So manipulate it. Short it. Shake the tree. Scare out the weak hands 😆 It's coming!💰🤑🔥

$ABCL I love the JP Morgan upgrade and especially the physician survey they conducted! The central thesis is that ABCL has reached a major value inflection point following the encouraging ABCL635 Phase 2 data for menopausal hot flashes. J.P. Morgan highlighted ABCL635’s potentially differentiated profile—particularly its efficacy, safety and dosing convenience—and cited a September physician survey in which roughly 60% of respondents said they could see at least 25% of their menopausal hot-flash patients using ABCL635, with the average expected penetration around 38%. The firm also emphasized AbCellera’s extensive pharmaceutical partnerships as validation of its antibody-discovery platform while helping offset development costs. When JP and Goldman starts coverage, you know there is money to be made!

$ABCL 🔥 Get in NOW!! We GOT a MAJOR CATALYST in a few days!!! After an “IMPRESSIVE & a HOME-RUN of Phase II RESULTS WE have.. Now been INVITED to PRESENT at the LARGEST 2026 TMS “THE MENOPAUSE SOCIETY” in the WORLD 🔥 STARTING NEXT TUESDAY!! 🚨Guess What, we are PRESENTING the 12 WEEK DATA 📊 for Phase II @ this CONFERENCE in front of Millions of People & Institutions and this will make itself known to the ENTIRE WORLD. 👂 🌍 If you thought 💭 that the Move for Phase II result was “BIG” your fooling yourself! This is the “BIG” move we been waiting for. When people hear ABOUT the 12 week Data 📊 and see the Results for themselves for 90 days. 😮 🤯 🔥 BOOM!! We going to SKY ROCKET $18-$23🚀! Carl CEO $ABCL in his own words said “Patient’s were CURED” YES “CURED”!! Patients went from experiencing “10 EVENTS a day to ZERO” in less than 4 weeks!! This is a “f******* “BIG”DEAL!! 🔥 They are going to be ADDING $ABCL to their portfolios and BUYING it UP!! The RESULTS are “flawless”!!! 🤯 🚀

$ABCL stay focused people….remember what Carl recently said! Carl Hansen appeared at the 12th Annual Cantor Fitzgerald Global Healthcare Conference, interviewed by analyst Steven Seedhouse. Some notable points: * Hansen said the ABCL635 results “blew the doors off” even their most bullish expectations. * He emphasized that ABCL635 isn’t the whole AbCellera story. * He said the platform and future drugs may ultimately be the most valuable part of the company. * ABCL has already put a longer-half-life follow-on to ABCL635 into IND-enabling studies. * Interestingly, Hansen suggested AbCellera may stop announcing development candidates before they enter the clinic, saying disclosure can expose the company without creating much value. * He indicated that two other programs could enter the clinic next year, which could give investors additional catalysts beyond ABCL635

$ABCL We're doing a pretty good job at treading water while the markets are making some very big adjustments. Would love to see some news\updates from the company to give us a jolt. I want to know what ABCL688 will be for, would love to know managements plan for ABCL 635 phase 3, still waiting for phase 1 readout for ABCL575 too. Happy Tuesday everyone!

$ABCL $BB these are my two favourites. If they want to drive it down for no good reason, I'm tempted to avg up. ABCL 3rd stage data! --> 20B MC min. BB Alloy Kore! --> 147 price min. Tickers are unrelated beyond being in Canada and both down today. I'm not leveraged and not leaving.

$ABCL good consolidation today, holding up very well considering how red the market is….. one catalyst and we are off to 15+. Be locked and loaded. Any day now!

$ABCL UBS initiated coverage of AbCellera (ABCL) with a Buy rating and $18 price target The firm believes ABCL635 is a “potentially transformative therapy” in menopausal hot flashes, with a $13B commercial opportunity in menopause by 2035. UBS models $3.3B menopause risk-adjusted 2035 sales versus the consensus at $1.5B. ABCL635 can capture greater share of a larger market than investors currently anticipate, the analyst tells investors in a research note.

$ABCL Still going higher jmho.. Holding every share. Insiders recently loaded it wasnt for $12.5 jmho

$ABCL boys. I usually am very quick on taking profits. But not here. On this one i hold tight. Thing is, this mf can blow up a couple hundred percent in a day or two with the right news.. but same thing applies the other way around. Invest money your ready to lose. Cause this could be the best or worst trade of your life. I never touch biotech, but ABCL got a convincing case going.

$ABCL folks, remain calm. The longs have seen this movie too often. I think a breather was long overdue. If you go back six months ago, we were in the $3 range. Today we are in the $13 range. $10 in six months is something to celebrate and be thankful. Perhaps we need our Moon Guy to cheerlead a little more😜

$ABCL scared money doesn’t make money. Picked up some more shares on the dip……. Now let’s rip!!